| Dr Adam Lynn Keathley, PHARMD | |
|
315 S James St, Jacksonville, AR 72076-4315 | |
| (501) 982-6979 | |
| (501) 241-1220 |
| Full Name | Dr Adam Lynn Keathley |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 315 S James St, Jacksonville, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083203442 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | PD12323 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Adam Lynn Keathley, PHARMD 8517 Trail Creek Dr, Sherwood, AR 72120-8089 Ph: (501) 563-2519 | Dr Adam Lynn Keathley, PHARMD 315 S James St, Jacksonville, AR 72076-4315 Ph: (501) 982-6979 |
News Archive
In decades of studying how neural circuits in the brain's visual cortex adapt to experience, MIT Professor Mark Bear's lab has followed the science wherever it has led, yielding the discovery of cellular mechanisms serving visual recognition memory, in which the brain learns what sights are familiar so it can focus on what's new, and of a potential therapy for amblyopia, a disorder where children born with disrupted vision in one eye can lose visual acuity there permanently without intervention.
Biotechnology company Arana Therapeutics Limited today provided an update on the major inflammatory compounds in its drug development pipeline. As part of this update, Arana said it has developed a new antibody candidate ART123, targeting inflammatory diseases and it plans to start a Phase I clinical trial for age-related macular degeneration (AMD) candidate PMX53 in 2009.
Practis, Inc., a distinguished healthcare web design firm, and Primetime Medical Software, the leading provider of patient interviewing technology, partnered to deliver Practis Forms—new healthcare software that allows practices to administer medical history and other clinical questionnaires securely through their current website.
Tasly Pharmaceutical Co., Ltd. and ProteoTech, Inc. today announced an agreement to co-develop ProteoTech's novel small molecule therapeutic, Exebryl-1(R), for the treatment of mild-to-moderate Alzheimer's disease.
A recent study by US researchers reveals that brilacidin, a small synthetic molecule with peptide-like properties, exerts potent in vitro antiviral activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – both as a standalone treatment and in combination with FDA-approved remdesivir. The study is currently available on the bioRxiv preprint server.
› Verified 9 days ago
Courtney Underwood, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2000 John Harden Dr, Jacksonville, AR 72076 Phone: 501-982-3357 Fax: 501-982-5578 | |
Bethany Brooke Dunn, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9913 Jones Rd, Jacksonville, AR 72076 Phone: 501-920-0142 | |
Jennifer L Wolff, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2000 John Harden Dr, Jacksonville, AR 72076 Phone: 501-982-3357 | |
Dr. Amanda Gail Bellamy, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1090 Arnold Dr, Jacksonville, AR 72099 Phone: 501-987-8981 | |
Tristan Phillips, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 103 Gregory Pl, Jacksonville, AR 72076 Phone: 501-985-0822 | |
Roderick Romes Jr., PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 103 Gregory Pl, Jacksonville, AR 72076 Phone: 501-985-0822 |